In CML, KMT2D (but also KMT2C) downregulation was found to correlate with the CML phases, and thus, disease progression, but also with the response of CML patients (Rabello et al., 2018). This evidence concerns the gene KMT2C and chronic myelogenous leukemia, BCR-ABL1 positive.